INCLUSION: - Histologically or cytologically confirmed diagnosis of R/M HNSCC that is considered not amenable to further therapy with curative intent. The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx (nasopharynx is excluded). - Known HPV p16 status for oropharyngeal cancer. EXCLUSION: - Has received prior IL2-based anti-cancer treatment.
University of Colorado Hospital
Antonio Jimeno, MD, PhD
Protocol Number: 21-4146
More information available at ClinicalTrials.gov: NCT05061420
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers